GSK announces positive results from DREAMM-8 phase III trial for ...
WEBMar 7, 2024 · Blenrep (belantamab mafodotin) plus PomDex showed statistically significant and clinically meaningful progression-free survival compared to bortezomib plus PomDex; Consistent efficacy results observed for Blenrep combinations in two phase III …
After withdrawal, GSK touts another Blenrep combo win as …
WEBMar 7, 2024 · In patients with previously treated multiple myeloma, Blenrep beat Takeda’s Velcade in their respective combinations with Bristol Myers Squibb’s Pomalyst and the corticosteroid dexamethasone, GSK...
FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for …
WEBBLENREP is a first-in-class anti-BCMA (B-cell maturation antigen) therapy for patients whose disease has progressed despite prior treatment with an immunomodulatory agent, proteasome inhibitor and anti-CD38 antibody. BLENREP is the fifth major medicine approval for GSK in 2020. Issued: London UK.
DREAMM-7 phase III trial shows Blenrep combination nearly tripled ... - GSK
WEBFeb 5, 2024 · GSK plc (LSE/NYSE: GSK) today announced results from an interim analysis of the DREAMM-7 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin) combined with bortezomib plus dexamethasone (BorDex) versus daratumumab plus BorDex in second-line and later treatment of relapsed or refractory multiple myeloma.
GSK details Blenrep combo data that could bring the multiple …
WEBFeb 5, 2024 · GSK telegraphed the latest phase 3 win in a surprise announcement in November, a year after the company pulled Blenrep as a monotherapy for heavily pretreated multiple myeloma patients in the...
DREAMM-8 Phase III Trial for Blenrep | Int'l Myeloma Foundation
WEBMar 7, 2024 · GSK press releases reports on positive results from DREAMM-8 phase III trial for Blenrep versus standard of care combination in relapsed/refractory multiple myeloma.
New data presented at ASH 2021 highlight potential of Blenrep
WEBDec 13, 2021 · GlaxoSmithKline (GSK) plc today announced new data from the DREAMM-9 (DRiving Excellence in Approaches to Multiple Myeloma) phase I trial and two GSK collaborative studies investigating the potential use of Blenrep (belantamab mafodotin-blmf), a first-in-class anti-BCMA (B-cell maturation antigen) therapy, in combination with standard of care th...
Phase III Blenrep Trial | Int'l Myeloma Foundation
WEBMonday, November 27, 2023 - 10:48. On November 27, 2023, GSK announced positive results from the DREAMM-7 phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma. The trial demonstrated a significant improvement in progression-free survival (PFS) when belantamab mafodotin was ...
FDA approves GSK's Blenrep for advanced multiple myeloma
WEBSep 15, 2024 · The FDA has approved GlaxoSmithKline’s multiple myeloma drug Blenrep, a first-in-class potential blockbuster that will be used in advanced disease. Blenrep (belantamab mafodotin) has been...
GSK's blood cancer drug meets primary goal in late-stage trial
WEBNov 27, 2023 · GSK said on Monday that its blood cancer drug Blenrep had reached a key goal in a late-stage trial, as the British drugmaker looks to bolster its oncology business after a series of setbacks.